Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Unknown 2Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 211Thoracic 72Head & Neck 25Other solid neoplasm 13Gynecologic 13Lymphoid 10Breast 8Tumor-Agnostic 7CNS 6Sarcoma 4Genitourinary 4Endocrine 3Other neoplasm 2NET 2Dermatologic 2Myeloid 1

Conditions

Neuroendocrine Tumors 2Carcinoma, Neuroendocrine 2Pancreatic Neoplasms 1

Interventions

Everolimus 59lutetium Lu 177 dotatate 46Magnetic Resonance Spectroscopy 33pembrolizumab 31Temozolomide 31Cisplatin 29Nivolumab 26Octreotide 24lanreotide 23cabozantinib 22pasireotide 21gallium Ga 68 dotatate 21lenvatinib 20Etoposide 19Specimen Handling 18Paclitaxel 18Carboplatin 18Capecitabine 18Sunitinib 17Bevacizumab 16trametinib 15dabrafenib 15Doxorubicin 143-Iodobenzylguanidine 14surufatinib 13Sorafenib 13Ipilimumab 13Thyrotropin Alfa 12Injections 12Positron Emission Tomography Computed Tomography 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × sintilimab × Endocrine × Clear all
NCT05165407 2025-03-14

NESSIE

Peking University

Phase 2 Recruiting
30 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT05627427 2022-11-25

Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard Chemotherapy

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
60 enrolled
EndocrineGastrointestinal

Pancreatic Neoplasms, Carcinoma, Neuroendocrine

NCT05113355 2021-11-24

Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm

Peking Union Medical College Hospital

Phase 2 Unknown
23 enrolled
EndocrineNET

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡